These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 27370607)
1. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. Hartmann S; Bhola NE; Grandis JR Clin Cancer Res; 2016 Aug; 22(16):4005-13. PubMed ID: 27370607 [TBL] [Abstract][Full Text] [Related]
2. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review). Liu D; Zhong M; Zhan D; Zhang Y; Liu S Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120 [TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. Raj S; Kesari KK; Kumar A; Rathi B; Sharma A; Gupta PK; Jha SK; Jha NK; Slama P; Roychoudhury S; Kumar D Mol Cancer; 2022 Jan; 21(1):31. PubMed ID: 35081970 [TBL] [Abstract][Full Text] [Related]
4. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718 [TBL] [Abstract][Full Text] [Related]
5. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725 [TBL] [Abstract][Full Text] [Related]
6. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Lim YC; Kang HJ; Moon JH Oral Oncol; 2014 Jul; 50(7):633-9. PubMed ID: 24835851 [TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway. Lau PC; Chan AT Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616 [TBL] [Abstract][Full Text] [Related]
8. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. Madoz-Gúrpide J; Zazo S; Chamizo C; Casado V; Caramés C; Gavín E; Cristóbal I; García-Foncillas J; Rojo F J Transl Med; 2015 Aug; 13():282. PubMed ID: 26319934 [TBL] [Abstract][Full Text] [Related]
9. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings. Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528 [TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233 [TBL] [Abstract][Full Text] [Related]
11. c-Met Signaling as a Therapeutic Target in Head and Neck Cancer. Centuori SM; Bauman JE Cancer J; 2022 Sep-Oct 01; 28(5):346-353. PubMed ID: 36165722 [TBL] [Abstract][Full Text] [Related]
12. The Influence of Met Receptor Level on HGF-Induced Glycolytic Reprogramming in Head and Neck Squamous Cell Carcinoma. Boschert V; Klenk N; Abt A; Janaki Raman S; Fischer M; Brands RC; Seher A; Linz C; Müller-Richter UDA; Bischler T; Hartmann S Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940827 [TBL] [Abstract][Full Text] [Related]
13. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma. De Herdt MJ; Baatenburg de Jong RJ Front Biosci; 2008 Jan; 13():2516-26. PubMed ID: 17981731 [TBL] [Abstract][Full Text] [Related]
14. HER2 as a therapeutic target in head and neck squamous cell carcinoma. Pollock NI; Grandis JR Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855 [TBL] [Abstract][Full Text] [Related]
15. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives. Bozec A; Peyrade F; Milano G Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267 [TBL] [Abstract][Full Text] [Related]
16. Activated HGF-c-Met Axis in Head and Neck Cancer. Arnold L; Enders J; Thomas SM Cancers (Basel); 2017 Dec; 9(12):. PubMed ID: 29231907 [TBL] [Abstract][Full Text] [Related]
17. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases. Whang YM; Jung SP; Kim MK; Chang IH; Park SI Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428 [TBL] [Abstract][Full Text] [Related]
18. Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Kumar D; New J; Vishwakarma V; Joshi R; Enders J; Lin F; Dasari S; Gutierrez WR; Leef G; Ponnurangam S; Chavan H; Ganaden L; Thornton MM; Dai H; Tawfik O; Straub J; Shnayder Y; Kakarala K; Tsue TT; Girod DA; Van Houten B; Anant S; Krishnamurthy P; Thomas SM Cancer Res; 2018 Jul; 78(14):3769-3782. PubMed ID: 29769197 [TBL] [Abstract][Full Text] [Related]
19. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Galeazzi E; Olivero M; Gervasio FC; De Stefani A; Valente G; Comoglio PM; Di Renzo MF; Cortesina G Eur Arch Otorhinolaryngol; 1997; 254 Suppl 1():S138-43. PubMed ID: 9065649 [TBL] [Abstract][Full Text] [Related]
20. Understanding c-MET signalling in squamous cell carcinoma of the head & neck. Szturz P; Raymond E; Abitbol C; Albert S; de Gramont A; Faivre S Crit Rev Oncol Hematol; 2017 Mar; 111():39-51. PubMed ID: 28259294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]